Navigation Links
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Date:11/22/2013

PARIS and TARRYTOWN, N.Y., Nov. 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the SARIL-RA-MOBILITY Phase 3 clinical trial in adult patients with active rheumatoid arthritis (RA) who were inadequate responders to methotrexate (MTX) therapy, sarilumab (the first fully-human anti-IL-6R monoclonal antibody) treatment in combination with MTX improved disease signs and symptoms as well as physical function, and inhibited progression of joint damage.

"IL-6 blockade is emerging as an important therapeutic approach for rheumatoid arthritis," said Neil Graham, M.B.B.S., M.D., M.P.H., Vice President, Program Direction, Immunology and Inflammation, Regeneron Pharmaceuticals.  "We are encouraged with these Phase 3 results, which demonstrated efficacy at both doses of sarilumab, each administered every other week."

The 52 week SARIL-RA-MOBILITY Phase 3 trial enrolled approximately 1,200 patients with active, moderate-to-severe rheumatoid arthritis, and who were inadequate responders to MTX therapy. Patients were randomized to one of three subcutaneous treatment groups, all in combination with MTX and dosed every other week: sarilumab 200 milligrams (mg), sarilumab 150 mg, or placebo.

Both sarilumab groups showed clinically relevant and statistically significant improvements compared to the placebo group in all three co-primary endpoints (p<0.0001).

(1) Improvement in signs and symptoms of RA at 24 weeks, as measured by the American College of Rheumatology score of 20 percent improvement (ACR20).

  • 66 percent, 58 percent, and 33 percent in the sarilumab 200 mg, sarilumab 150 mg, and placebo groups respectively, all in combination with MTX.
  • (2) Improvement in physical function, as measured by change from baseline in the Health Assessm
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
    2. Sanofi US Launches Collaborate Activate Innovation Challenge
    3. Sanofi Pasteur to add 2D barcode to six more vaccines
    4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
    5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
    6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
    7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
    8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
    9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
    10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
    11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
    (Date:7/30/2015)... Calif. , July 30, 2015  Cleave ... and Trademark Office has granted the company a ... covering Cleave,s lead molecule CB-5083. This ... as inhibitors of p97," U.S. 9,062,026, allows for ... a first-in-class, highly selective oral inhibitor of p97, ...
    (Date:7/30/2015)... Flexpoint Ford, a private equity firm focused ... that it has entered into a partnership with ... form Kastle Therapeutics, LLC (Kastle).  The new company, headquartered ... acquiring, developing and commercializing pharmaceuticals targeted toward diseases with ... therapies already approved for marketing, as well as clinical ...
    Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
    ... DIEGO, Feb. 6, 2012   Neurelis, Inc. today announced ... (FDA) has cleared an Investigational New Drug application ... of NRL-1 for the treatment of acute breakthrough ... late 2011, Neurelis filed the IND based upon ...
    ... Association (PCMA) launched a new ad campaign in Oregon ... (PBMs).  The ad campaign – "That,s What PBMs ... , PBMs lower costs for employers, unions, and consumers ... , PBMs help patients make informed prescription drug decisions ...
    Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2PCMA Launches New Oregon Ad Campaign: 'That's What PBMs Do' 2
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels ... Waycross, Georgia. Start time will be 7:30 AM. The duathlon is a 2 mile run, ... swim in Laura Walker Lake, a 13 mile bike, and a 3 mile run. ...
    (Date:7/31/2015)... ... July 31, 2015 , ... With the recent buzz ... individuals who remain undiagnosed, treatment options for patients are becoming more prevalent than ... therapy due to its overall lack of comfort and highly invasive nature, oral ...
    (Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
    (Date:7/30/2015)... , ... July 30, 2015 , ... OSF Healthcare ... results from the 2015 Most Wired Survey conducted by Hospitals & Health Networks. This ... system owned and operated by The Sisters of the Third Order of St. ...
    (Date:7/30/2015)... ... 2015 , ... In a meaningful ritual intended to symbolize a final farewell ... have created an addiction graveyard. Sharing this with the public comes at a unique ... Hudson . Hudson (1945-2015) fell in love with the desert when he moved from ...
    Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
    ... , , WASHINGTON, July 31 ... for Tobacco-Free Kids: , , (Logo: ... D.C. Council has taken an important step to protect the District,s kids ... cigarette tax by 50 cents to $2.50 per pack - the seventh ...
    ... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
    ... , , , Campaign ... After 4 months of college students and others wrestling with ... picked two winners for its nationwide sign design contest. The victors ... who is entering law school this fall at the University of ...
    ... , ALBANY, N.Y., July 31 ... New York throughout the week of August 3 - 7 ... New Yorkers access information on programs that provide prescription medicines for ... 8.2 percent, compared to 5.2 percent a year ago, the ...
    ... , , Partnership for ... WASHINGTON, July 31 The House Energy and Commerce ... legislation that would prohibit cost-sharing to Medicaid patients for recommended ... was supported by Partnership for Prevention, the American College of ...
    ... WASHINGTON, July 31 Last night, U.S. Rep. Lois Capps ... H.R. 3200, that would specifically include abortion in the health care ... Council Action President Tony Perkins had this to say on the ... up: , , "It has been clear ...
    Cached Medicine News:Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 3Health News:House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2
    ... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
    For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
    For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
    For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
    Medicine Products: